Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Upstream Bio (NASDAQ:UPB) has scheduled a conference call and webcast for September 2, 2025, at 8:00 a.m. ET to present top-line data from its Phase 2 VIBRANT trial. The study evaluates verekitug, a unique monoclonal antibody targeting TSLP receptor, in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
The VIBRANT trial (NCT06164704) is a global, randomized, placebo-controlled study where participants received either 100 mg of verekitug or placebo subcutaneously every 12 weeks for 24 weeks. The trial's primary endpoint focuses on measuring changes in endoscopic nasal polyp score at Week 24.
Details
News Market Reaction – UPB
On Sep 2, the first trading day after this news, UPB closed 18.27% above the previous close. That session’s volume was 5.1x the stock’s average daily volume.
Data tracked by StockTitan Argus for the Sep 2 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
– Conference Call and Webcast to be held Tuesday, September 2, 2025, at 8:00 a.m. ET –
WALTHAM, Mass., Sept. 01, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced it will report top-line data from the Phase 2 VIBRANT trial of verekitug, the only known clinical-stage monoclonal antibody targeting the receptor for thymic stromal lymphopoietin (TSLP), on Tuesday, September 2, 2025.
The VIBRANT trial (NCT06164704) was a Phase 2 global, randomized, placebo-controlled, parallel group clinical trial designed to assess the efficacy and safety of verekitug in adults with CRSwNP. Participants received either 100 mg of verekitug or placebo subcutaneously every 12 weeks for 24 weeks. The primary endpoint was change in endoscopic nasal polyp score (NPS) at Week 24.
Conference Call and Webcast
Upstream Bio’s conference call and webcast to discuss the top-line data results from the Phase 2 VIBRANT trial will begin Tuesday, September 2, 2025, at 8:00 a.m. ET. The live webcast can be accessed via this link or on the Events tab on the Investors section of the Company’s website at https://investors.upstreambio.com/news-events/events. A replay of the webcast will be available on the website following the call.
About Upstream Bio
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in clinical development that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. The Company has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and chronic obstructive pulmonary disease (COPD). Upstream Bio’s team is committed to maximizing verekitug’s unique attributes to address the substantial unmet needs for patients underserved by today’s standard of care. To learn more, please visit www.upstreambio.com.
Investor and Media Contact: Meggan Buckwell Director, Corporate Communications and Investor Relations ir@upstreambio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.